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Epidemic hypotension in a dialysis center caused by sodium azide The
water used for dialysate (dialysis fluid) in hemodialysis centers is
produced by water treatment systems (WTS), which require careful and
frequent monitoring. On November 3, 1988, nine patients receiving
hemodialysis treatments at a single dialysis center suddenly developed
hypotension within 30 minutes of onset of dialysis. Eight patients
exhibited symptoms and two experienced syncopal episodes; there
were no deaths. The incidence of dialysis-associated hypotension
occurring within 30 minutes after dialysis onset for these patients was
significantly higher during outbreak treatments than during preoutbreak(September 1 through November 2, 1988) treatments, (9 of 9 vs. 0 of
238, P < 0.00001, Fisher's t-test). Sodium azide, a potent hypotensive
agent, was identified as the probable contaminant within the WTS of the
dialysis center at the time of the outbreak because: I) it was mixed with
glycerine as the preservative solution of each of the four ultrafilters that
were put on-line in the WTS without rinsing, 12 hours before the
outbreak; and 2) high levels of total organic carbons were detected from
dialysis water collected at point-of-use sites at the time of the outbreak,
suggesting contamination of the WTS with the sodium azide-glycerine
preservative solution. To prevent similar occurrences, we recommend
that ultrafilters (and other components of the WTS) be rinsed free of
potentially toxic chemicals prior to use. Dialysis center personnel need
to be aware of the potential affects that each modification or disinfection
of the WTS may have upon the product water used to prepare dialysate
for patient treatments.
The Association for the Advancement of Medical Instrumen-
tation (AAMI) recommends that water used for the production
of dialysate (dialysis fluid) should be treated to remove organic
and inorganic substances and microbial contaminants [1]. Cer-
tain chemicals in water are harmless when ingested but toxic to
hemodialysis patients who can be exposed to 150 liters of water
per treatment. Adverse affects have occurred among patients
exposed to dialysis water containing high concentrations of
aluminum (dialysis dementia) [2—3], zinc [4], copper [5], fluo-
rides [6], calcium [7], sodium [8], chloramines [9, 101, and
hydrogen peroxide (Centers for Disease Control, unpublished
data).
We report an outbreak of epidemic hypotension among a
group of patients during hemodialysis treatments in a dialysis
unit in New York State during November 1988, in which the
dialysate was inadvertently contaminated with sodium azide.
Background
The dialysis unit has been in operation at its present location
since January 1982. The unit has 19 dialysis stations. At the
time of the investigation 71 adults were receiving chronic
hemodialysis with Lundia IC plate dialyzers' (Gambro Lundia,
AB, Sweden) and Gambro AK-b dialysis monitors (Gambro
Lundia, AB, Sweden). The acetate or bicarbonate concentrate
was proportioned automatically at each individual monitor.
Dialyzers were not reused.
Water treatment system
The water treatment system (WTS) at the dialysis unit
consisted of: 1) pretreatment; 2) the ultrafilter loop; 3) the
reverse osmosis (RO) unit; 4) the distribution loop which
included 19 dialysis stations and a 600 gallon holding tank (Fig.
1).
Community supplied water was distributed through the hot
and cold water lines at the dialysis center, mixed to approxi-
mately 26°C, and flowed sequentially through a sand filter, a
carbon filter, and a 10-micron cotton sediment filter.
The water next passed through four hollow-fiber ultrafilters
aligned in parallel, and into a ultrafilter water holding tank. A
pump maintained adequate operating pressure within the ul-
trafilter loop to permit continuous recirculation of ultrafilter
treated water from the ultrafilter holding tank through the
ultrafilter recirculation loop. Upon demand, water flowed from
the ultrafilter distribution 1oop to the RO unit. To reduce
accumulated debris, back-flushing of the ultrafilters occurred
automatically at 1830 and 0100 hours.
The RO unit includes a 1-micron prefilter, a pump to maintain
the operating pressure required to operate the RO unit, and two
RO cartridges, each containing two RO membrane nodules. The
RO membranes are set up in a single pass 1: 1 serial array. The
rejected water (effluent) was run-off to a drain, while the
permeate (RO product water) passed through to the 600-gallon
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Ultrafilter
membranes
capacity RO holding tank. The RO unit was activated to fill the
RO holding tank upon demand.
A pump, located adjacent to the RO holding tank, continu-
ously recirculated RO product water from the tank to the 19
dialysis stations. If the dialysis stations were not in use, the
water returned via approximately 400 feet of piping to the RO
holding tank.
Modification of the WTS on November 2, 1988
Between 1800 and 2000 hours on November 2, 1988, work-
men completed three modifications of the WTS at the dialysis
unit. First, an auxiliary electrical system was installed to
provide a back-up source of power to the pumps within the
WTS. The integrity of the WTS was not violated during this
process. Second, an additional (5 hp) pump was installed
adjacent to the RO storage tank to provide an increased rate of
flow of product water within the distribution loop for the
anticipated expansion of dialysis stations. New plumbing con-
necting the RO storage tank, the new pump, and the distribution
loop was fitted; this process required the RO storage tank water
to be drained to a level of approximately 40 gallons. Third, the
four ultrafilters on-line (GM8O-HF53 Romicon, Inc., Woburn,
Massachusetts, USA) were replaced with four new identical
ultrafilters per routine maintenance protocol. Each ultrafilter is
composed of 2940 non-cellulosic synthetic polymer hollow
fibers 43 in length and 0.1 micron thick, with an approximate
surface area of 53 sq ft. Prior to shipping, the hollow fibers are
treated with a preservative (0.25% sodium azide and 25%
glycerine solution). The manufacturer recommends a rinse
procedure to flush out both the ultrafilter hardware and car-
tridge before installation. However, no warning label or instruc-
tions were included with the shipment of the new ultrafilters,
and they were not rinsed before being put on-line in the WTS.
At 2000 hours on November 2, 1988 the WTS was put back
on-line. Dialysis treatments resumed at 0610 hours on Novem-
ber 3, 1988.
The incident of epidemic hypotension among patients
receiving dialysis treatments
Between 0610 and 0715 hours on November 3, 1988, nine
patients began their regularly scheduled dialysis treatments. By
0730 hours, nursing personnel identified significant signs and
symptoms of hypotension among several patients; all dialysis
treatments were stopped by 0805 hours. Contamination of the
water within the WTS was suspected as the cause for these
adverse reactions because of the modifications of the WTS
performed during the previous evening. Water at point-of-use
stations was checked for chloramines and chlorine and tested
negative. Additional fluid specimens were collected from a
single point-of-use station, the distribution loop, the RO storage
tank, and from the faucet. Serum samples were collected from
each patient at 0830 hours along with samples from the dialyz-
ers used during their treatments. The WTS was bypassed using
Sand Carbon 1O
filter filter Cotton
filter
Fig. 1. The water treatment system of a New York dialysis center, November 1988.
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tubing to connect the dialysis machines to tap water faucets,
and hemodialysis treatments resumed at 1100 hours. Subse-
quently, two mixed-bed deionization tanks were installed
within the WTS on November 5 at 1700 hours, bypassing both
the ultrafilters and the RO unit, providing deionized water to the
point-of-use distribution loop.
Epidemiologic investigation
During the epidemic period, defined as the period of time
between 0610 and 0815 on November 3, several patients receiv-
ing hemodialysis experienced sudden onset of unexplained
symptomatic hypotension. We wanted to answer the following
questions: 1) Was the incidence of hypotension among these
particular patients undergoing chronic hemodialysis unusual?
and 2) Did these patients experience hypotension as a result of
their dialysis treatments with water contaminated within the
WTS?
Methods
A case was defined as any patient who had undergone dialysis
at the dialysis unit between 0610 and 0815 hours on November
3, 1988, who had a fall in systolic blood pressure >50 mm Hg
from the blood pressure measurement obtained immediately
before treatment to a level <90 mm Hg, or a fall in systolic
blood pressure 80 mm Hg from the blood pressure measure-
ment obtained immediately prior to treatment to a level 100
mm Hg, within 30 minutes after onset of hemodialysis.
We defined hypotension during hemodialysis as a fall in
systolic blood pressure >30 mm Hg from the blood pressure
measurement obtained immediately before treatment to a level
<90 mm Hg at any time after onset of dialysis.
We reviewed the records of the case-patients for dialysis
treatments occurring immediately prior to, during, and after the
outbreak exposure treatment on November 3. Data collected
included: patient age, race, sex; cause of end-stage renal
disease; total years of hemodialysis; total number of hemodial-
ysis treatments at the dialysis unit; dialyzer type; which dialysis
machine; date, onset and duration of hemodialysis treatments;
pre-, intra-, and postdialysis vital signs (including onset of
lowest recorded intradialytic blood pressure); symptoms of
nausea and emesis, headache, cramps, subjective chills, or
rigors; and receipt of intradialytic medications; including intra-
venous fluids or blood products. All nine patients were inter-
viewed by the investigators concerning the events of November
3. The nephrologists, nursing personnel, and individual in
charge of maintenance of the WTS were also interviewed by
investigators.
To determine whether an outbreak had occurred we com-
pared predialysis, intradialysis, and postdialysis blood pressure
measurements and heart rates of case-patients during the out-
break and the dialysis sessions immediately following the
outbreak. To control for potential factors, a side from contam-
inated dialysis fluid, that may have contributed to the develop-
ment of hypotension during treatment, we compared the morn-
ing dialysis sessions of the case-patients to their dialysis
sessions later in the day. Only the source of the water used to
dilute the dialysate concentrate to produce dialysate differed
between the two treatment sessions; in the morning session the
dialysis fluid was produced from the WTS product water and in
the afternoon session tap water was used. The type of dialyzers
(same lot numbers), the type of dialysate concentrate, the
dialysis stations, and the particular dialysis monitors were the
same for both treatment sessions for all 9 patients.
To evaluate whether the case-patients may have been predis-
posed to developing hypotension or other adverse reactions
during their hemodialysis, we conducted a cohort study. We
reviewed 1672 consecutive hemodialysis treatments among all
patients receiving treatment at the dialysis unit from September
1 through November 1, 1988 (the preoutbreak period) for
adverse reactions during dialysis. The dialysis records of the
case-patients and non-case-patients were reviewed for signs
and symptoms of hypotension, headache, pyrogenic reactions,
cramps, nausea and emesis, and other miscellaneous complica-
tions (itching, myalgia, chest discomfort).
Laboratory methods
We collected water and dialysate samples to measure bacte-
rial and endotoxin concentrations at several locations along the
WTS. Each sample was collected in a sterile, pyrogen-free
tube, refrigerated, and sent to the Centers for Disease Control
(CDC) for testing. Specimens were cultured and endotoxin
levels measured within 48 hours of collection. Viable cell
counts in fluid samples were determined with the membrane
filtration technique using R2A agar. After the filters (0.45
micron) were incubated for 72 hours at 30°C, colonies were
counted. Bacterial endotoxin measurements were determined
by the LAL5000Tm turbidimetric assay system using Limulus
amebocyte lysate (Pyrotel, Associates of Cape Cod, Cape Cod,
Massachusetts, USA).
Water specimens were collected at points along the WTS
before and after flushing of the WTS with deionized water on
November 3. These samples were tested for total organic
carbons (TOC) and sodium azide concentrations by Upstate
Laboratories (Syracuse). Serum specimens collected from all
nine patients at 0830 hours on November 3 were also tested for
sodium azide concentrations.
Total organic carbons were determined from a 1-ml fluid
sample with a T.O.C. analyzer (0! Corporation, College Sta-
tion, Texas, USA). Ion liquid chromatography was used to
measure the total sodium azide content in 50 to 100-ul fluid
samples.
Statistical analysis
Proportions were compared using the chi-square test. The
significance of difference between means was assessed by
Fisher's t-test.
Results
Epidemiologic investigation
All nine patients who underwent dialysis during the morning
session of November 3 met the case definition for outbreak-
associated hypotension (Table 1). Eight of nine patients (89%)
exhibited symptoms; the patient without symptoms had a
decline in systolic blood pressure of 88 mm Hg during her
treatment. The frequency of symptoms among case-patients
included: headache, six patients (67%); blurry vision, five
patients (56%); nausea or emesis, three patients (33%); and
syncope, two patients (22%). All patients recovered completely
within 5 to 40 minutes after discontinuing dialysis.
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Table 1. Clinical characteristics of case-patients in a dialysis unit in New York, November 3, 1988
November 3
Patient Age Sex
Prior number
of CHD
treatments
Time of
onset
hours Duration
Blood pressure mm Hg
SymptomsPre Intraa Post
1 65 M 520 0610 20 170/98 50/30 134/80 BY; HA; N/E
2 66 M 405 0613 66 180/90 60/40 128/72 BY; HA; SYNCOPE
3 64 M 570 0630 60 110/80 40/— 138/66 BY; HA; SYNCOPE
4 71 M 751 0630 45 156/80 90/— 167/80 BY; HA; CR
5 67 F 1119 0715 45 180/80 100/60 160/90 BY
6 61 F 1142 0635 90 188/62 100/54 120/80 NONE
7 65 M 1097 0640 40 138/80 70/40 120/60 HA
8 75 M 154 0645 30 140/78 84/40 138/76 N/E
9 52 F 421 0655 20 148/72 64/42 154/78 HA; N/E
Abbreviations are: CHD, chronic hemodialysis; BY, blurred vision; HA, headache; N/E, nausea/emesis; CR, cramps.
a Single lowest recorded value
The nine case-patients began their dialysis treatments be-
tween 0610 and 0715 hours at dialysis stations located at several
points along the distribution loop, which suggested a common
source of exposure. The mean values for the lowest single
systolic and diastolic blood pressures recorded during dialysis
for case-patients differed significantly between their morning
and afternoon dialysis sessions on November 3, (73/34 mm Hg
vs. 122/62 mm Hg, P < 0.002). The mean values for case-
patients' pretreatment and posttreatment systolic and diastolic
blood pressure measurements and heart rate did not differ
significantly between sessions. Only one patient developed
hypotension (asymptomatic) during hemodialysis in the later
session, (systolic blood pressure dropped from 105 mm Hg to 72
mm Hg at 180 minutes after onset of dialysis). In contrast,
case-patients had significantly lower systolic and diastolic blood
pressures than did non-case-patients during the outbreak pe-
riod. No episodes of headache, nausea or emesis, cramps,
rigors, fever, or syncope occurred during the later dialysis
sessions. These results suggested that an outbreak had occurred
and that the water from the WTS appeared to be the source of
the outbreak.
Next, we compared the characteristics and signs and symp-
toms of case-patients and non-case-patients during preoutbreak
dialysis sessions (September 1 through November 1, 1988), to
determine whether case-patients had risk factors for or were
more likely to have adverse reactions during dialysis. During
the preoutbreak period, hypotension occurred in 255 (15.2%)
episodes of the dialysis treatments. Ninety percent (229) of
these episodes occurred more than 60 minutes after the onset of
dialysis (median; 180 minutes); 24 (9.4%) occurred between 30
and 60 minutes after the onset of dialysis and two episodes of
hypotension (including one cardiac arrest due to arrhythmia)
occurred within 30 minutes of the onset of dialysis. The
incidence of other adverse outcomes during dialysis were:
nausea or emesis; 91 episodes (5.4%); cramps; 67 (4%); head-
ache; 23 (1.4%); miscellaneous symptoms (itching, chest dis-
comfort, myalgia); 23 (0.1%); no pyrogenic reactions were
identified.
Among the host factors evaluated for the two patient groups,
only the mean number of chronic hemodialysis treatments
differed significantly (630 treatments for case-patients vs. 249
for non-case patients, P = 0.001). During the preoutbreak
period, there was no significant difference in the incidence rate
of hypotension during dialysis treatments for the case-patients
and non-case-patients. For other adverse reactions, only the
incidence of cramping during hemodialysis was significantly
associated with case-patients (24 episodes in 238 treatments for
case-patients vs. 43/1,434 for noncase patients, P < 0.001).
These results suggest that no particular host factor among the
nine case-patients were associated with the occurrence of
hypotension during dialysis treatments.
The incidence of hypotension during dialysis treatments for
the case-patients was significantly higher during the outbreak
period than during the preoutbreak period (9/9 vs. 27/238, P <
0.00001). We compared preoutbreak and outbreak hypotensive
episodes of case-patients: 1) onset at <30 minutes after the
onset of dialysis (9/9 vs. 0/238); 2) onset >30 minutes and 60
minutes after the onset of dialysis (0/9 vs. 0/238); 3) >60
minutes after the onset of dialysis (0/9 vs. 27/238). The differ-
ence between the incidences was significantly different for only
the episodes of hypotension that occurred within the initial 30
minutes of treatment, (P < 0.00001). These data show that the
incidence of hypotensive episodes among case-patients was
significantly greater during the outbreak period than during the
preoutbreak period and that this difference was due to the
increased rate of hypotension within 30 minutes of onset of
dialysis.
We reviewed the dialysis records of 17 of the 19 patients who
received hemodialysis immediately following the previous ex-
change of ultrafilters on April 17, 1987 but found no signs or
symptoms of dialysis associated hypotension. There was no
documentation of whether the ultrafilters had been rinsed
before they were installed.
Laboratory results
Microbiologic investigation. The highest concentrations of
bacteria and endotoxins were found in city water and points
early in the WTS (endotoxin concentrations ranged from 8.7 to
62.8 ng/ml, and bacterial counts ranged from 17 to 3300 CFU/
ml). The water used to prepare the dialysate and the dialysate
specimens collected during treatment were generally within the
AAMI maximum recommended microbial concentrations for
water used to prepare dialysis fluid (<200 CFU/ml) and for
dialysate (<2,000 CFU/ml).
Chemical analysis. Sodium azide was not detected in water
samples obtained from the WTS (lower detection limit of 5
114 Gordon et a!: Sodium azide and hypotens ion
Table 2. Chemical results for total organic carbons and sodium azide
of water specimens and patient serum specimens, New York,
November 3—4, 1988
Sample site and time
collected
Total organic
carbons Sodium azidea
mg/liter
Water specimens from the
distribution loop
November 3, 1000 33 <5
hours, prior to rinsing
of WTS
November 3, 2000 4.7 <5
hours, after rinsing of
WTS
November 4, 0900 <1 <5
hours, after rinsing of
WTS
Patient serum specimen&'
November 3, 0830 hours — <0.5
a By ion liquid chromatography.b Includes all 9 case-patients.
mg/liter; Table 2). However, TOC levels were elevated (normal
<1 mg/liter), within the distribution ioop at 1000 hours on
November 3 and declined to nondetectable levels within 24
hours of rinsing the WTS with deionized water. Sodium azide
was not detected in the blood of the nine case-patients obtained
at 0830 hours on November 3 (lower detection limit of 50 parts
per billion).
Discussion
This cluster of hypotensive episodes among patients ap-
peared to be due to a contaminant in the WTS, probably sodium
azide, which resulted in contaminated dialysate. This outbreak
underscores the potential for adverse reactions secondary to
inadvertent introduction of contaminants into the WTS in a
dialysis unit. All nine patients who were undergoing dialysis at
the time of the outbreak experienced significant signs or symp-
toms of hypotension within minutes of the onset of dialysis.
Although hypotension among patients receiving hemodialysis
during the preoutbreak period was not unusual (15% incidence),
episodes of hypotension occurring within 30 minutes of onset of
dialysis were very infrequent (<0.1% incidence). In this out-
break, there was a significant increase in the incidence of
hypotensive episodes occurring within 30 minutes of the onset
of dialysis treatments.
The rapid onset of symptoms, the high attack rate among
patients throughout the unit, and the fact that symptoms
resolved quickly and completely within minutes of discontinu-
ation of dialysis suggested a common source exposure to a
hypotensive agent. Localization of the source to the WTS of the
dialysis unit is supported by the observation that all nine
case-patients subsequently underwent dialysis without incident
later on the same day when only the treatment of the water used
to produce dialysis fluid had been changed.
If sodium azide, which is known to cause hypotension in
humans, was the contaminant, it probably came from the four
unrinsed new ultrafilters put on-line 12 hours before the hy-
potensive event. Water specimens collected from the distribu-
tion ioop at the time of the outbreak tested negative for sodium
azide but contained high TOC concentrations. The high TOC
content could be explained by the presence of glycerine, which
was used with azide as a preservative solution for the new
ultrafilters. The glycerine concentration within the preservative
solution was 100 times that of sodium azide and may explain
why an elevated TOC concentration (and not sodium azide
concentration) was detected within the WTS.
Sodium azide is a colorless neutral stable salt of hydrazoic
acid and was once extensively used as a preservative of serum
and other reagents in bacteriologic labs. In vitro studies have
shown that it inhibits cytochrome oxidase and other enzymes
[11]. The toxicity of sodium azide ingestion or inhalation has
been reported in studies of lab personnel, workers involved in
lead azide manufacturing, and persons who have committed
suicides [11—15]. It is a very potent hypotensive agent, produc-
ing vasodilatation via its direct action on smooth muscle. The
hypotensive dose of sodium azide in humans is 0.2 to 4.0 p.glkg
[15, 16]. Symptoms of dysphoria, headache, nausea, and dim-
ness of vision have also been reported with small doses. Large
ingested doses in humans produce convulsions and death. The
signs and symptoms observed in the nine case-patients are
consistent with the pharmacologic effects of sodium azide;
therefore it was the likely contaminate in the dialysis fluid that
caused this outbreak.
The manufacturer of the ultrafilters estimates that 0.8 g of
sodium azide was contained within a single ultrafilter cartridge.
Using an approximate total volume of 1000 gallons within the
WTS, a 50% rejection rate of feed water by the RO membranes,
and a dialysis fluid flow rate set at 500 mI/mm, we determined
that a hypotensive dose of sodium azide (300 p.g) could be
delivered to a 70 kg man within the first five minutes of dialysis
treatment.
In 1986, 1350 chronic hemodialysis centers in the United
States representing approximately 90,000 dialysis patients were
surveyed; only 12 (<1%) of the centers did not indicate use of
a WTS [17]. Deionizers with or without reverse osmosis mem-
branes were the most common components within WTS as
reported by hemodialysis centers. The Food and Drug Admin-
istration (FDA) considers a WTS within a dialysis center to be
a medical device when it is intended to remove organic and
inorganic substances and microbial contaminants from water
used to prepare dialysis fluid [18]. As with other Class II
medical devices (such as, blood access devices), a WTS within
a dialysis center is subject to performance standards in addition
to general controls. Although AAMI has published guidelines
for the quality of water used to prepare dialysis fluid, to date the
WTS in hemodialysis centers has not been regulated. The task
of regulation is made difficult by the large number of dialysis
centers, each of which uses a WTS with a unique design. When
installing a new WTS or modifying an existing one, the owner!
operator of the dialysis center may consult with different
manufacturers of WTS or with a qualified water engineer
familiar with the special needs of dialysis facilities [10]. In
addition, because the dialysis center does not sell the uniquely
configured WTS, the owner/operator is not required to register
as a medical device manufacturer.
This was the third time during 1988 that adverse reactions
occurring in dialysis patients exposed to chemically contam-
inated dialysis fluid were investigated by officials from FDA and
CDC. In all instances, patient morbidity might have been
avoided if the dialysis centers had properly rinsed their WTS
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after disinfection, maintenance or modification, and if appropri-
ate chemical test kits were used prior to and during resumption
of dialysis. We suspect that similar events have occurred but
have gone unreported.
Prevention
The cornerstone of prevention of WTS complications in
hemodialysis patients is recognizing that water produced by a
WTS is a dynamic system subject to changes occurring outside
and within the dialysis center, and it therefore requires careful
and frequent monitoring of all aspects of the WTS for potential
problems. We recommend the following to practitioners as a
guideline to prevent chemical contamination within the WTS:
1. Each hemodialysis center must employ an individual
qualified in routine maintenance of the WTS. This person must
be familiar with the chemicals used for disinfection of their
water sources and with the WTS in use.
2. When changes in the WTS are being considered, all
components of the system and their interaction should be
evaluated before any changes are implemented. After modifi-
cations (including replacement of used components), dialysis
center personnel need to ensure that the water used to prepare
dialysis fluids meets AAMI standards, and is free from toxic
chemicals.
3. Ultrafilters should be installed according to the manufac-
turer's recommendations and care should be taken to rinse each
ultrafilter thoroughly before being put on-line within the WTS
[19].
4. After a WTS disinfection, water from several point-of-use
stations should be tested for residual disinfectant with an
appropriate indicator before dialysis treatments are resumed.
5. Because many municipal water treatment facilities rou-
tinely add chloramines to the water supply which can be
harmful to dialysis patients if allowed to remain in the water
used to prepare dialysates, practitioners must be assured that
the maximum expected level of chloramines from the municipal
water supply can be effectively removed by the WTS [10]. We
recommend the use of charcoal filters containing granular
activated carbon (GAC) and replace rather than regenerate the
filters when exhausted.
6. Finally, clusters of adverse reactions or infections occur-
ring among patients during dialysis should be reported immedi-
ately to local and state health departments and to the Office of
Compliance, Device Monitoring Branch, Center for Devices &
Radiological Health, Food and Drug Administration [Tele-
phone: (301) 427-81441.
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